Skip to main content
To KTH's start page To KTH's start page

Research program 1

The success of protein drugs over small molecular drugs relates to higher specificity, activity and longer in vivo half-life, which has made them increasingly dominant on the list of blockbuster drugs. These are most often produced in mammalian cell lines, such as the workhorse Chinese Hamster Ovary cell line (CHO), successfully serving to produce IgG and other challenging biologics for many decades. Several upcoming next-generation biologics as well as some of the human natively secreted proteins, however display difficulties in production in active processed form at the high yields needed in CHO. This program area headed by PI Johan Rockberg addresses these issues in two subprojects run by KTH in close collaboration with the partner companies.

Project

Put together a toolbox for tuning of protein secretion in CHO. Including overexpression of limiting factors and down-regulation of counteracting regulators.
PI: Professor Johan Rockberg
PhD student: Niklas Thalén

P1 Reducing product aggregation with helper genes.pdf (pdf 755 kB)

P1 Comparing the omics landscapes of HEK293 and CHO for improved bioproduction.pdf (pdf 1.2 MB)

Partner companies: